An assessment of prevalence of Type 1 CFI rare variants in European AMD, and why lack of broader genetic data hinders development of new treatments and healthcare access

  1. Jones, A.V.
  2. Curtiss, D.
  3. Harris, C.
  4. Southerington, T.
  5. Hautalahti, M.
  6. Wihuri, P.
  7. Mäkelä, J.
  8. Kallionpää, R.E.
  9. Makkonen, E.
  10. Knopp, T.
  11. Mannermaa, A.
  12. Mäkinen, E.
  13. Moilanen, A.-M.
  14. Tezel, T.H.
  15. Waheed, N.K.
  16. Arora, R.
  17. Crawford, C.
  18. Creuzot-Garcher, C.
  19. Csaky, K.
  20. Devin, F.
  21. Eichenbaum, D.
  22. Ferrone, P.
  23. Figueroa, M.
  24. Flaxel, C.
  25. Ghorayeb, G.
  26. Gilmour, D.
  27. Grisanti, S.
  28. Guymer, R.
  29. Hall, E.
  30. Heier, J.
  31. Ho, A.
  32. Hoyng, C.
  33. Issa, P.C.
  34. Ivanova, T.
  35. Kaluzny, B.
  36. Khanani, A.
  37. Leveziel, N.
  38. Maturi, R.
  39. McKibbin, M.
  40. Nielsen, J.
  41. Schneiderman, T.
  42. Spitzer, M.
  43. Steele, D.
  44. Suan, E.
  45. Tezel, T.H.
  46. Voleti, V.
  47. Wirthlin, R.
  48. Show all authors +
Journal:
PLoS ONE

ISSN: 1932-6203

Year of publication: 2022

Volume: 17

Issue: 9 September

Type: Article

DOI: 10.1371/JOURNAL.PONE.0272260 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

Data source: Scopus